Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Choreo LLC

Choreo LLC grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 109.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,354 shares of the medical research company’s stock after purchasing an additional 1,755 shares during the period. Choreo LLC’s holdings in Thermo Fisher Scientific were worth $1,781,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the stock. Raleigh Capital Management Inc. grew its position in shares of Thermo Fisher Scientific by 49.1% in the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 27 shares during the period. Cedar Mountain Advisors LLC grew its position in shares of Thermo Fisher Scientific by 107.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 46 shares during the period. Operose Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 250.0% in the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after buying an additional 75 shares in the last quarter. Financial Connections Group Inc. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $53,000. Finally, Valley National Advisers Inc. raised its stake in Thermo Fisher Scientific by 40.5% during the third quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock worth $56,000 after purchasing an additional 32 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders have sold a total of 52,277 shares of company stock valued at $29,649,264 in the last ninety days. 0.34% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. HSBC lifted their target price on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a research note on Tuesday. Evercore ISI boosted their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Citigroup started coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target on the stock. Raymond James lifted their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Finally, Barclays boosted their price target on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $607.35.

Thermo Fisher Scientific Stock Down 1.4 %

TMO stock opened at $568.74 on Wednesday. The company has a fifty day moving average price of $574.58 and a 200 day moving average price of $531.67. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a market cap of $217.09 billion, a price-to-earnings ratio of 36.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.59 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.